基于细胞因子的癌症和淋巴瘤免疫治疗：生物学、挑战与未来展望。
Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives.
机构信息
Department of Hematology and Medical Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.
出版信息
Front Immunol. 2022 Apr 20;13:872010. doi: 10.3389/fimmu.2022.872010. eCollection 2022.
Abstract
Cytokines regulate both the innate and adaptive immune responses to cancer. Although antitumor activity has been seen for several cytokines in preclinical models, they have had limited success as single therapeutic agents in clinical trials of cancer immunotherapy. However, the possible combinations of cytokines with other immune therapeutics and the advancement in genetic engineering, synthetic biology and cellular and immune therapy has led to the revival of interest in cytokines as anticancer agents. This article will review several immunostimulatory cytokines with anticancer activity, focusing on the those that have been studied in treatment of lymphoma and highlighting recent advances of potential clinical relevance.
摘要
细胞因子调节着癌症的固有免疫和适应性免疫反应。虽然几种细胞因子在临床前模型中表现出抗肿瘤活性，但作为癌症免疫治疗临床试验中的单一治疗药物，它们的效果有限。然而，细胞因子与其他免疫疗法的可能组合以及遗传工程、合成生物学和细胞与免疫治疗的进步，使得人们重新对细胞因子作为抗癌药物产生了兴趣。本文将综述几种具有抗肿瘤活性的免疫刺激细胞因子，重点介绍那些已在淋巴瘤治疗中进行研究的细胞因子，并强调具有潜在临床相关性的最新进展。
相似文献
1
Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives.基于细胞因子的癌症和淋巴瘤免疫治疗：生物学、挑战与未来展望。
Front Immunol. 2022 Apr 20;13:872010. doi: 10.3389/fimmu.2022.872010. eCollection 2022.
2
Engineering interferons and interleukins for cancer immunotherapy.工程干扰素和白细胞介素用于癌症免疫治疗。
Adv Drug Deliv Rev. 2022 Mar;182:114112. doi: 10.1016/j.addr.2022.114112. Epub 2022 Jan 24.
3
Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.抗体-细胞因子融合蛋白：用于调节抗肿瘤免疫的多功能产品。
Cancer Immunol Res. 2019 Mar;7(3):348-354. doi: 10.1158/2326-6066.CIR-18-0622.
4
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].干扰素和白细胞介素与放疗联合的抗肿瘤作用。第一部分：免疫学基础
Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x.
5
Immunotherapy of cancer by IL-12-based cytokine combinations.基于白细胞介素-12的细胞因子组合对癌症的免疫治疗。
Expert Opin Biol Ther. 2007 Nov;7(11):1705-21. doi: 10.1517/14712598.7.11.1705.
6
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.为癌症免疫疗法定制生物材料：新兴趋势与未来展望。
Adv Mater. 2017 Aug;29(29). doi: 10.1002/adma.201606036. Epub 2017 May 26.
7
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.抗癌细胞因子：干扰素-α2、白细胞介素（IL）-2、IL-15、IL-21和IL-12的生物学特性及临床效应
Semin Oncol. 2015 Aug;42(4):539-48. doi: 10.1053/j.seminoncol.2015.05.015. Epub 2015 Jun 3.
8
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy.局部支架辅助递呈免疫治疗药物以改善癌症免疫治疗。
Adv Drug Deliv Rev. 2022 Jun;185:114308. doi: 10.1016/j.addr.2022.114308. Epub 2022 Apr 23.
9
Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications.细胞因子/细胞因子基因导向治疗局部给药系统的开发：现代肿瘤学意义。
Curr Oncol Rep. 2022 Apr;24(4):389-397. doi: 10.1007/s11912-022-01221-3. Epub 2022 Feb 10.
10
Biological therapy of ovarian cancer: current directions.卵巢癌的生物治疗：当前方向
Semin Oncol. 1998 Jun;25(3):381-96.
引用本文的文献
1
Mapping the role of cytokine signaling at single-cell and structural resolution in uveal melanoma.在葡萄膜黑色素瘤中以单细胞和结构分辨率绘制细胞因子信号传导的作用。
Genes Immun. 2025 Jun 9. doi: 10.1038/s41435-025-00337-3.
2
Anti-Proliferative Activity of Ethylenediurea Derivatives with Alkyl and Oxygen-Containing Groups as Substituents.含烷基和含氧基团作为取代基的乙二脲衍生物的抗增殖活性
Biomedicines. 2025 Jan 29;13(2):316. doi: 10.3390/biomedicines13020316.
3
Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy.新型抗癌药物的分子生物学：聚焦激酶抑制剂、生物制剂和嵌合抗原受体T细胞疗法。
Inflamm Res. 2025 Feb 17;74(1):41. doi: 10.1007/s00011-025-02008-5.
4
Advancements and challenges in immunocytokines: A new arsenal against cancer.免疫细胞因子的进展与挑战：对抗癌症的新武器库。
Acta Pharm Sin B. 2024 Nov;14(11):4649-4664. doi: 10.1016/j.apsb.2024.07.024. Epub 2024 Aug 2.
5
Intratumoral injection and retention hold promise to improve cytokine therapies for cancer.瘤内注射和保留有望改善癌症的细胞因子疗法。
Front Oncol. 2024 Aug 26;14:1456658. doi: 10.3389/fonc.2024.1456658. eCollection 2024.
6
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.用于癌症治疗的肿瘤归巢抗体-细胞因子融合物
Onco Targets Ther. 2024 Aug 29;17:697-715. doi: 10.2147/OTT.S480787. eCollection 2024.
7
Targeting cytokine and chemokine signaling pathways for cancer therapy.针对细胞因子和趋化因子信号通路的癌症治疗。
Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3.
8
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy.转化性药代动力学/药效学与PD1/IL15的首次人体剂量选择：一种用于癌症免疫治疗的工程重组靶向细胞因子
Front Pharmacol. 2024 Jun 3;15:1380000. doi: 10.3389/fphar.2024.1380000. eCollection 2024.
9
Alginate-Chitosan Biodegradable and Biocompatible Based Hydrogel for Breast Cancer Immunotherapy and Diagnosis: A Comprehensive Review.基于海藻酸盐-壳聚糖的可生物降解和生物相容性水凝胶在乳腺癌免疫治疗和诊断中的应用：全面综述。
ACS Appl Bio Mater. 2024 Jun 17;7(6):3515-3534. doi: 10.1021/acsabm.3c00984. Epub 2024 May 24.
10
Causal relationship between circulating cytokines and follicular lymphoma: a two-sample Mendelian randomization study.循环细胞因子与滤泡性淋巴瘤之间的因果关系：一项两样本孟德尔随机化研究。
Am J Cancer Res. 2024 Apr 15;14(4):1577-1593. doi: 10.62347/JCKD6973. eCollection 2024.
本文引用的文献
1
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy.T细胞接合免疫疗法，重点介绍嵌合抗原受体（CAR）T细胞疗法。
Cancers (Basel). 2021 Dec 1;13(23):6067. doi: 10.3390/cancers13236067.
2
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis.干扰素治疗真性红细胞增多症和原发性血小板增多症的临床结局：系统评价和荟萃分析。
Int J Hematol. 2021 Sep;114(3):342-354. doi: 10.1007/s12185-021-03171-1. Epub 2021 Jun 6.
3
Clinical Application of Cytokines in Cancer Immunotherapy.细胞因子在癌症免疫治疗中的临床应用。
Drug Des Devel Ther. 2021 May 27;15:2269-2287. doi: 10.2147/DDDT.S308578. eCollection 2021.
4
Therapeutic potential of interleukin-15 in cancer (Review).白细胞介素-15在癌症治疗中的潜力（综述）
Exp Ther Med. 2021 Jul;22(1):675. doi: 10.3892/etm.2021.10107. Epub 2021 Apr 24.
5
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.异体 CAR T 细胞：克服胶质母细胞瘤 CAR T 细胞治疗挑战的一种选择。
Front Immunol. 2021 Mar 3;12:640082. doi: 10.3389/fimmu.2021.640082. eCollection 2021.
6
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.白细胞介素-18 结合蛋白是一种分泌型免疫检查点和白细胞介素-18 免疫治疗的障碍。
Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24.
7
IL-15 in the Combination Immunotherapy of Cancer.白细胞介素 15 在癌症联合免疫治疗中的作用
Front Immunol. 2020 May 19;11:868. doi: 10.3389/fimmu.2020.00868. eCollection 2020.
8
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.克服 CAR T 细胞疗法当前障碍的工程策略。
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167. doi: 10.1038/s41571-019-0297-y. Epub 2019 Dec 17.
9
Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.白细胞介素-15（异常）调节淋巴组织稳态：对自身免疫和癌症治疗的影响。
J Exp Med. 2020 Jan 6;217(1). doi: 10.1084/jem.20191062.
10
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.人源化白细胞介素 15 和单倍体异体自然杀伤细胞治疗急性髓细胞白血病的首次人体试验。
Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.
Zotero 插件